Current partner codePEPTIDESDE

Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression

Status

Recruiting

Phase

Phase 2 / Phase 3

Enrollment

400

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors

Full detailed description

Octreotide is an artificial replacement for the natural growth hormone inhibitor in humans. It is a small peptide hormone consisting of 14 amino acids and is widely distributed in neuroendocrine cells, with the highest density in the brain, peripheral neurons, endocrine pancreas and gastrointestinal tract. Under pathological conditions, some tumour cells show overexpression of growth inhibitory receptors, such as endocrine tumours of the pancreas, pituitary adenomas, pheochromocytomas, paragangliomas, carcinoid tumours, medullary thyroid carcinomas, small cell lung carcinomas Hepatocellular carcinoma, and meningioma. Therefore, the sensitivity and specificity of octreotide imaging is high. This study will provide a visual, reproducible and non-invasive imaging method for the diagnosis of SSTR positive tumors through Al18F-octreotide PCT/CT imaging, providing an intuitive and clear imaging basis for clinical diagnosis, differential diagnosis and treatment, contributing to the development of medicine and science in the field of positron imaging.

Interventions

Treatment arms and agents.

DRUG

Al18F-octreotide

Al18F-octreotide I was injected into the patients before the PET/CT scans

Timeline

From registration to results.

  1. First posted

    Mar 1, 2023

  2. Study start

    Dec 20, 2022

  3. Primary completion

    Dec 20, 2028

  4. Study completion

    Dec 20, 2029

  5. Results posted

    Not reported

  6. Registry updated

    Apr 6, 2026

Outcomes

What the study measures.

Primary outcomes

Diagnostic value

Time frame · through study completion, an average of 1 year]

Sensitivity and Specificity of Al18F-octreotide PET/CT for SSTR positive tumors

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Patients with suspected or clearly diagnosed SSTR positive tumors * signed written consent. * Willing and able to cooperate with all projects in this study. Exclusion Criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Study locations

1 registered sites.

China. Showing up to 24 locations stored in the fast local snapshot.

National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Chao Yang, China

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Octreotide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.